Welcome to our dedicated page for Vertex Pharmaceuticals SEC filings (Ticker: VRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vertex Pharmaceuticals filings document the biotechnology company’s operating results, governance and product-development disclosures. Recent Form 8-K reports include quarterly and annual results releases, selected regulatory and pipeline events involving therapies such as povetacicept, and officer or director transition disclosures.
The company’s proxy materials cover board composition, director nominees, shareholder meeting matters, executive compensation and equity-award information. Vertex filings also provide formal records for disclosure topics tied to its approved medicines, clinical pipeline and governance structure as a Nasdaq-listed operating company.
Vertex Pharmaceuticals executive Edward Morrow Atkinson III reported a tax-related share disposition. On February 13, 2026, he disposed of 1,903 shares of Vertex common stock at $487.76 per share as a tax-withholding disposition and now directly holds 20,143 shares of common stock.
Vertex Pharmaceuticals senior executive reports tax-related share disposition
Vertex Pharmaceuticals' SVP & Chief Accounting Officer Kristen Ambrose reported a Form 4 transaction involving a tax-withholding disposition of 1,393 shares of common stock at $487.76 per share on February 13, 2026. This type of transaction reflects shares withheld to cover tax obligations, rather than an open-market sale. After this transaction, Ambrose directly owns 8,734 shares of Vertex common stock.
Ourania Tatsis reported multiple secondary sales of common stock in filings relating to VRTX. The reported transactions list sales of 4,500 shares on 12/03/2025, 4,500 shares on 01/07/2026, 466 shares on 02/11/2026, 1,500 shares on 02/13/2026, and 609 shares on 02/17/2026. The excerpt also shows 368 shares associated with restricted stock vesting from the issuer on 02/17/2026.
Jonathan P. Biller reported sales of Common stock under Rule 144. The filing lists sales of 12/03/2025 ($155,803 for 347 shares), 02/11/2026 ($886,327.75 for 1,925 shares), 02/13/2026 ($493,012 for 988 shares) and 02/17/2026 ($1,211,902.96 for 2,476 shares).
The form also shows a Restricted Stock Vesting entry dated 02/17/2026 with a numeric reference of 1,244, listed under "Securities To Be Sold" with the method described as Compensation.
Vertex Pharmaceuticals reported insider transactions and a restricted‑stock vesting event. The filing lists 1,182 common shares under "Securities To Be Sold" tied to Restricted Stock Vesting on 02/17/2026 as "Issuer" compensation. The filing also records sales by Mark E. Bunnage: 23 shares on 12/29/2025 (10,649.00), 2,021 shares on 02/11/2026 (930,529.03), and 2,437 shares on 02/17/2026 (1,192,814.02).
Vertex Pharmaceuticals filed a Form 144 reporting proposed and recent transactions in its common stock. The filing lists 817 shares to be sold on 02/17/2026 tied to restricted stock vesting, and prior sales by E Morrey Atkinson of 1,751 shares on 02/11/2026 and 2,031 shares on 02/17/2026.
Vertex Pharmaceuticals (VRTX) insider Mark Bunnage filed a notice to sell 2,437 shares of Vertex common stock through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $1,192,814.02, with an approximate sale date of February 17, 2026.
The shares to be sold were acquired on February 13, 2026 via restricted stock vesting from the issuer as compensation. Over the prior three months, Bunnage sold 2,021 Vertex common shares on February 11, 2026 for gross proceeds of $930,529.03 and 23 shares on December 29, 2025 for $10,649.00.
An affiliate of VRTX, identified as Ourania Tatsis, has filed a notice to sell 609 shares of common stock through Fidelity Brokerage Services on NASDAQ around 02/17/2026. These shares were acquired on 02/13/2026 via restricted stock vesting as compensation from the issuer.
The filing also lists recent sales over the prior three months. On 12/03/2025 and 01/07/2026, Tatsis sold 4,500 common shares each, with gross proceeds of 2024955.40 and 2137455.00. Additional sales on 02/11/2026 and 02/13/2026 covered 466 and 1,500 shares, with proceeds of 214560.38 and 749992.02.
An affiliated shareholder has filed notice of an intended sale of 2,476 shares of common stock through Fidelity Brokerage Services LLC on or around February 17, 2026 on the NASDAQ. The filing lists an aggregate market value of $1,211,902.96 for these shares, compared with 254,034,190 shares outstanding.
The shares to be sold were acquired on February 13, 2026 through restricted stock vesting from the issuer as compensation. The notice also details prior sales in the last three months by Jonathan P. Biller, including several smaller common‑stock transactions.
Vertex Pharmaceuticals executive Edward Atkinson has filed a notice of proposed share sales under Rule 144. The filing covers the planned sale of 2,031 shares of Vertex common stock through Fidelity Brokerage Services LLC on or about 02/17/2026 on NASDAQ, with an aggregate market value of 994093.26 at the time of the notice.
The 2,031 shares to be sold were acquired on 02/13/2026 via restricted stock vesting from the issuer as compensation. Over the past three months, Atkinson has already sold 2,500 Vertex common shares on 11/17/2025 for gross proceeds of 1086450.00, and 1,751 shares on 02/11/2026 for gross proceeds of 806212.93. The filing also notes that the seller represents not being aware of undisclosed material adverse information about the company.